Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Theranos

Explore full profile

Blood testing and early disease detection services

Palo Alto, United StatesFounded 2003Biotech & Life Sciences
Headcount 100–500 Current team size
Total funding $500M–1B Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Theranos and the history behind them.

About Theranos

Theranos Inc. was a privately held health technology company that became a cautionary tale of Silicon Valley ambition. Founded in 2003 by a 19-year-old Stanford University dropout, Elizabeth Holmes, the company, originally named Real-Time Cures, set out with a compelling mission. Holmes, who studied chemical engineering before leaving Stanford, aimed to revolutionize the diagnostics industry. Her vision was inspired by her own fear of needles and an idea to develop a wearable patch for drug delivery and blood monitoring. She used her tuition money to launch the venture.

The company's central claim was that it had developed a proprietary technology capable of running hundreds of blood tests on just a few drops of blood obtained from a simple finger prick. This device, later known as the 'Edison' machine, promised to make blood testing faster, cheaper, and more accessible to consumers. The business model focused on establishing direct-to-consumer "Wellness Centers," primarily through a major partnership with Walgreens, to offer these tests at a fraction of the cost of traditional labs. Theranos also claimed its technology was deployed by the U.S. Department of Defense on the battlefield, a statement later proven false. The company raised over $700 million from private investors and venture capitalists, reaching a peak valuation of $9 billion between 2013 and 2014, making Holmes, on paper, the world's youngest self-made female billionaire.

In 2009, Ramesh "Sunny" Balwani, Holmes's then-boyfriend whom she had met as a teenager, joined the company as president and chief operating officer, despite having no background in medicine or medical technology. The company operated under a strict veil of secrecy, which would later be identified as a key factor in its ability to conceal its fraudulent activities. The turning point came in October 2015, when investigative journalism from The Wall Street Journal, spurred by whistleblowers, questioned the validity of Theranos's technology. It was revealed that the company was performing only a small fraction of its tests on its proprietary devices and was instead using commercially available, sometimes modified, machines from other manufacturers for the vast majority of its analyses. The results from its own technology were often inaccurate, leading to misdiagnoses for actual patients. Following these revelations, the company faced a cascade of legal and regulatory challenges, including investigations by the SEC, CMS, and federal prosecutors. Walgreens terminated its partnership, and Theranos voided two years of test results. In March 2018, the SEC charged Holmes and Balwani with massive, years-long fraud. Holmes settled the charges, agreeing to a $500,000 fine, relinquishing control of the company, and accepting a 10-year ban from serving as an officer or director of a public company. The company ultimately dissolved in September 2018. Both Holmes and Balwani were later indicted on criminal charges of wire fraud and conspiracy, and both were convicted and sentenced to over 11 and 12 years in prison, respectively.

Source: Dealroom company data

At a glance

Founded
2003
Headquarters
Palo Alto, United States
Sector
Biotech & Life Sciences

Investors

16 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

Series A2 investors entered at this stage

  • Rupert Murdoch
  • ATA Ventures

Series B and later13 investors entered at this stage

  • Tako Ventures
  • The Lawrence J. Ellison Revocable Trust
  • Continental Properties
  • Walgreen
  • Jupiter Partners
  • Esoom Enterprise
  • B.J. Cassin
  • PFM Health Sciences
  • Blue Venture Fund
  • Palmieri Family Trust
  • Raymond Bingham
  • Puget Sound Venture Club
  • Fortress Investment Group
Team profiled 44 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 8 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇬🇧 United Kingdom2.9%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Theranos on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Theranos on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.